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Summary
Cowden syndrome (CS) is an autosomal dominant
disorder associated with the development of
hamartomas and benign tumors in a variety of tissues,
including the skin, thyroid, breast, endometrium, and
brain. It has been suggested that women with CS are at
increased risk for breast cancer. A locus for CS was
recently defined on chromosome 10 in 12 families,
resulting in the identification of the CS critical interval,
between the markers D10S215 and D10S541. More
recently, affected individuals in four families with CS
have been shown to have germ-line mutations in a gene
known as “PTEN,” or “MMAC1,” which is located in
the CS critical interval on chromosome 10. In this study,
we report three novel MMAC1 mutations in CS and
demonstrate that MMAC1 mutations are associated
with CS and breast cancer. Furthermore, we also show
that certain families and individuals with CS do not have
mutations in the coding sequence of MMAC1. Finally,
we did not detectMMAC1mutations in a subpopulation
of individuals with early-onset breast cancer, suggesting
that germ-line mutations in this gene do not appear to
be common in this group.
Introduction
Cowden syndrome (CS) (Lloyd and Dennis 1963), or
multiple hamartoma syndrome (Weary et al. 1972), is
an autosomal dominant disorder associated with the de-
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velopment of hamartomas and benign tumors in a va-
riety of tissues, including the skin, thyroid, breast, en-
dometrium, and brain. It has been suggested that women
with CS are at increased risk for breast cancer (Brown-
stein et al. 1978), and, as in other susceptibility syn-
dromes, they appear to develop breast cancer at an early
age (Schrager et al., in press). CS is also associated with
a specific skin lesion, trichilemmoma (tumor of the fol-
licular infundibulum), and thus this breast can-
cer–susceptibility syndrome can be recognized by the
presence of a cutaneous biomarker (Brownstein et al.
1977, 1978). We have studied in detail the clinical and
pathological findings (Schrager et al., in press) in this
syndrome and have demonstrated that the mean age at
presentation with malignant breast disease in CS is 46
years, with the age range at presentation with breast
cancer in affected women being 33–74 years (Schrager
et al., in press). Moreover, very few of the women with
CS whom we studied had a family history of breast
cancer (Schrager et al., in press). Of interest is that men
with CS appear not to be at increased risk for the de-
velopment of breast cancer (Brownstein et al. 1978;
Schrager et al., in press). We have also shown that
women with CS develop exuberant benign breast disease
and frequently report a history of multiple breast bi-
opsies prior to the development of breast cancer. The
history of skin disease and benign breast disease can
therefore allow identification of affected individuals
prior to the development of breast cancer in this high-
risk population.
It has been demonstrated in a previous study that a
locus for CS exists on chromosome 10 (Nelen et al.
1996). In that study, a total of 12 families were exam-
ined, resulting in the identification of the CS critical in-
terval as being between markers D10S215 and
D10S564. Certain affected individuals in these families
had CS and Lhermette-Duclos disease (LDD) (Nelen et
al. 1996; Liaw et al. 1997), a rare brain disorder char-
acterized by a dysplastic gangliocytoma of the cerebel-
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lum (Albrecht et al. 1992). Fine mapping of this area
refined this initial result (Liaw et al. 1997), supporting
a location, for the CS gene, between markers D10S215
and D10S215. More recently, affected individuals in
four families with CS have been shown to have germ-
line mutations (Liaw et al. 1997) in a gene known as
“PTEN” (Li et al. 1997), “MMAC1” (Steck et al. 1997),
or “TEP1” (Li et al. 1997), which is located in the CS
critical interval on chromosome 10. Of interest is that
the predictedMMAC1 protein contains sequence motifs
with significant homology to the catalytic domain of
protein phosphatases and to the cytoskeletal proteins,
tensin and auxillin (Li et al. 1997; Steck et al. 1997).
Moreover, coding-region mutations in MMAC1 have
been observed in human tumors or tumor cell lines of
the breast, brain, prostate, and kidney (Li et al. 1997;
Steck et al. 1997). Although the function of this gene is
unknown, it is likely that MMAC1 plays a role in the
control of cell proliferation and that its loss of function
is important in the development of human tumors.
Material and Methods
Clinical Material
Approval for this study was obtained by the Investi-
gation Review Board of Columbia PresbyterianMedical
Center. Blood samples were obtained after informed con-
sent was obtained from individuals with CS. An aliquot
was used for DNA extraction, while peripheral-blood
mononuclear cells were purified from a second sample
and were used to generate an Epstein-Barr vi-
rus–transformed lymphoblastoid cell line. The diagnosis
of CS was made on the basis of the International Cow-
den’s Consortium CS diagnostic criteria (Nelen et al.
1996). For individuals with early-onset breast cancer, the
sample consists of 63 women who developed breast can-
cer at age !35 years (average age at diagnosis 27.7
years), who did not have a clinical diagnosis of CS, and
who had previously been shown not to carry clearly
deleterious mutations in BRCA1 (5 women in the sample
carried missense polymorphisms of unknown signifi-
cance) (Shattuck-Eidens et al. 1997). These women are
a subset of a sample of 798 unrelated individuals from
20 collaborating institutions, chosen from families that
were generally at an elevated risk of carrying BRCA1
mutations. Most families were chosen because of mul-
tiple cases of breast cancer, early age at diagnosis of
breast cancer, and incidence of ovarian cancer, since
these conditions have been previously shown to be as-
sociated with germ-line mutations of BRCA1. Some of
the families were extended to second-degree relatives.
All samples from institutions in the United States were
collected from individuals participating in research stud-
ies on the genetics of breast cancer. Each individual read
and signed informed-consent documents approved by
the local institutional review board. All samples from
institutions outside the United States were collected ac-
cording to the appropriate guidelines, concerning re-
search involving human subjects, imposed by the insti-
tution’s equivalent authorities. Only one representative
from each family was included in the sample, and no
families in which genetic markers showed linkage to
BRCA1 were included. All the samples used in the
MMAC1 study were stripped of identifiers. This is a
heterogeneous sample that represents the diversity
among patients who present at high-risk clinics, as op-
posed to the more controlled sampling done for family
or population studies. This has directed our analyses
toward methods that do not require that sample fre-
quencies of subgroups reflect frequencies in the general
population. Therefore we can assess, for example, the
probability that a woman with breast cancer diagnosed
at age 30 years carries a deleterious BRCA1 orMMAC1
mutation, but we cannot estimate the frequency of such
women in the general population.
DNA Extraction
After informed consent was obtained, patients’ ge-
nomic DNAwas extracted fromwhole blood or lympho-
blastoid cell lines by use of the QIAamp Blood Maxi
Kit. Concentration was measured by optical density 260
(OD260), and purity was checked by the ratio OD260:
OD280.
Genotyping
Primer pairs for the chromosome 10 locus were ob-
tained from Research Genetics. The forward-strand pri-
mer was end-labeled in the presence of 33P-gATP and
polynucleotide kinase. PCR reactions were performed in
a total reaction volume of 30 ml. The reactions consisted
of 10 mM each primer, 200 mM deoxynucleotides, 1.5
units of Taq DNA polymerase, and 50 ng of genomic
DNA. PCR was performed for 35 cycles, with 45 s de-
naturation at 94C, 45 s annealing at 55C, and 1 min
elongation at 72C; a final 10-min elongation was used.
PCR reactions were stopped by addition of 20 ml of stop
solution (95% formamide, 1 mM EDTA, 0.25% brom-
ophenol blue, and 0.25% xylene cyanol). Then reactions
were denatured for 5 min at 94C, and the products
were separated on an 8%denaturing polyacrylamide gel.
Allele sizes were determined by comparison to
SequaMark (Research Genetics), which was included as
a size standard on the gels.
Linkage Analysis
Two-point linkage analysis was performed by use of
MLINK. The status of individuals of age !20 years was
considered as unknown. Disease-gene frequency was set
equal to .000001, and marker-allele frequencies were
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Table 1
Two-Point Analysis of CS Families with CA-Repeat Markers
FAMILY AND
MARKER
LOD SCORE FOR RECOMBINATION FRACTION OF
.0 .01 .05 .1 .2 .3 .4
A:
D10S579 .00 .00 .00 .00 .00 .00 .00
D10S215 .30 .30 .28 .26 .20 .15 .08
D10S541 .00 .00 .00 .00 .00 .00 .00
D10S1739 .30 .30 .28 .26 .20 .15 .08
D10S564 .30 .30 .28 .26 .20 .15 .08
B:
D10S579 .00 .00 .00 .00 .00 .00 .00
D10S215 .30 .29 .26 .21 .13 .06 .02
D10S541 .00 .00 .00 .00 .00 .00 .00
D10S1739 .30 .29 .26 .21 .13 .06 .02
D10S564 .30 .29 .26 .21 .13 .06 .02
C:
D10S579 .00 .00 .00 .00 .00 .00 .00
D10S215  3.40 2.00 1.40 .80 .44 .19
D10S541 .00 .00 .00 .00 .00 .00 .00
D10S1739 .05 .06 .09 .13 .16 .15 .09
D10S564  3.40 2.00 1.40 .80 .44 .19
D:
D10S579  1.52 .28 .11 .28 .19 .05
D10S215  1.58 .33 .07 .25 .18 .05
D10S541  1.44 .39 .01 .22 .18 .06
D10S1739 2.20 .45 .14 .32 .35 .23 .08
D10S564 .03 .08 .30 .38 .35 .22 .07
estimated by use of ILINK. Both MLINK and ILINK
are from the LINKAGE package, version 5.2 (Lathrop
et al. 1984). Reconstruction of the most probable hap-
lotypes in family D was accomplished by use of GENE-
HUNTER (Kruglyak et al. 1996). Pedigrees were drawn
by use of Cyrillic, version 2.02.
Mutation Detection
We performed nested PCR amplifications on ge-
nomic DNAs and screened the resulting amplicons for
sequence variants, as described elsewhere, with several
modifications (Steck et al. 1997). First, exon 6 was
screened as a single secondary amplicon amplified by
use of the exon 6 FB-RR primer pair. Second, exon 8
was screened as two secondary amplicons by use of
the following FB-RQ and FC-RR primers: CA6.HB
(5′-GTTTTCCCAGTCACGACGAGGTGACAGATT-
TTCTTTTTTA-3′) and CA6.HQ (5′-AGGAAACAG-
CTATGACCATTCGGTTGGCTTTGTCTTTA-3′);
and CA6.HC (5′-GTTTTCCCAGTCACGACGCAT-
TTGCAGTATAGAGCGT-3′) and CA6.HR (5′-AGG-
AAACAGCTATGACCATAGCTGTACTCCTAGAAT-
TA-3′). Third, since mononucleotide runs in certain
introns caused poor dye-primer sequencing, we ob-
tained dye-terminator sequence data on secondary
amplicons exon8 FB-RQ and exon 9 FB-RR, using the
nested primers 5′-TTTTTTTTTAGGACAAAATGTT-
TC-3′ and 5′-AATTCAGACTTTTGTAATTTGTG-3′.
We obtained 195% double-stranded coverage of the
MMAC1 coding sequence, for all genomic DNAs
screened; all mutations were confirmed by sequencing
of a newly amplified product.
Results
Linkage Analysis and Mutation Screening In CS
Kindreds
In order to extend the observations indicating a CS
locus on chromosome 10, we performed a two-point
linkage analysis using five markers located in the CS
critical interval, on four families with clinical evidence
of CS (Nelen et al. 1996). All families were examined
in detail, and the diagnosis of this syndrome was made
on the basis of the International Cowden’s Consortium
CS diagnostic criteria (Nelen et al. 1996). Two small
families displayed positive LOD scores that could not
exclude linkage to three loci on chromosome 10 (see
data on families A and B; table 1). Two other families,
with clinical findings identical to those described above,
showed significant negative LOD scores for some of the
markers in this region (families C and D; table 1). A
heterogeneity test was also performed, which gave non-
significant results (data not shown). These findings were
confirmed by the haplotypes’ construction (fig. 1). In
particular, in family C, individual 2 transmits to both
her affected children the haplotype inherited from her
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Figure 1 Haplotype construction with markers on chromosome 10 in four families with CS
Table 2
CS Mutations in Present Study
Mutation Exon/Intron Predicted Effect
791insAT Exon 7 Frameshift
915del13 Exon 8 Frameshift
137ins3 Exon 2 One-amino-acid
insertion (Asn)
unaffected father. Finally, in family D, individuals 2 and
20 have inherited a haplotype different from that of their
affected relatives.
Using a PCR- and sequencing-based approach, we ex-
amined the nine exons and associated splice junctions
of MMAC1, using the described primers (Steck et al.
1997), in 16 affected individuals from these four fami-
lies. Of interest is that 4 of these 16 individuals had
breast cancer and that 2 of these 4 had breast cancer at
age !40 years. We detected no mutations in the coding
sequence in these 16 individuals from these four families
with the classic symptoms and signs of CS.
Mutational Analysis in Individuals with CS
We then screened a set of 31 affected individuals from
23 families with CS whose kindreds had not been used
in our linkage studies (see table 2). Of the 31 individuals,
13 were related individuals from five families. Thus, a
total of 23 unrelated probands were screened. A single
affected female (Walton et al. 1986) demonstrated a
frameshift mutation in exon 7 of the coding sequence
(see fig. 2). Specifically, we demonstrated an AT insertion
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Figure 2 DNA Sequencing of MMAC1 in a family with CS and early-onset breast cancer. The affected mother (blackened circle) dem-
onstrates a 2-bp insertion (AT) in exon 5, which is not seen in her unaffected brother (unblackened square). Her affected daughter has inherited
the AT insertion.
after nucleotide 791 (791insAT), which resulted in a
frameshift and downstream premature termination co-
don. Of interest is that this woman developed mam-
mogram-negative breast cancer at age 36 years, which
was discovered at the time of prophylactic mastectomy
(Walton et al. 1986). The proband had an unaffected
brother as well as an affected daughter. Direct sequenc-
ing of exon 7 in these individuals demonstrated both the
presence of the identical mutation in the affected daugh-
ter (fig. 2) and the absence of the mutation in the un-
affected brother. In studying a second individual with
CS and early-onset (age 33 years) breast cancer, we dem-
onstrated a 3-bp insertion in exon 2 (137ins3), resulting
in the insertion of a single amino acid (Asn). Finally, in
another woman, who had bilateral breast cancer (Schra-
ger et al., in press) and endometrial cancer, we identified
a 13-bp frameshift deletion in exon 8 (915del12). These
data demonstrate three additional mutant alleles of
MMAC1 that are associated with CS (Liaw et al. 1997)
and, in particular, with CS and breast cancer (Brownstein
et al. 1978; Schrager et al., in press). However, in 27
individuals from 20 families, we did not detectmutations
in the coding sequences of MMAC1. In this population,
seven of these individuals had breast cancer, although
all of these women developed breast cancer at age 140
years. One of these seven individuals had bilateral breast
cancer. In total, therefore, combining the family data and
the data from these individuals, we detected coding-se-
quence mutations in 4 individuals from 3 CS families
but did not detect coding-sequence alteratons (i.e., mis-
sense or silent variants) in 43 other individuals from 24
families with CS.
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Mutational Analysis in Women with Early-Onset Breast
Cancer
A strong case has been made for the existence of a
genetic mechanism regulating breast-tumor formation in
early-onset breast cancer (i.e., the development of breast
cancer at age !40 years) (Claus et al. 1990). Since CS
is inherited in an autosomal dominant fashion, the ge-
netic mechanisms regulating the development of breast
cancer in this population may also play a role in the
development of early-onset breast cancer. Since we de-
tected germ-line MMAC1 mutations in CS associated
with early-onset breast cancer, and since mutations in
this gene occur at relatively high frequency in breast
tumors and in breast-tumor cell lines (Li et al. 1997;
Steck et al. 1997), we wanted to further investigate the
role of germ-line MMAC1 mutations in early-onset
breast cancer. In an effort to bias ourselves toward a
sample set potentially enriched in germ-line MMAC1
mutations, we sequenced the gene in 63 women who
had developed breast cancer at age !35 years (average
age at diagnosis 27.7 years) and who had previously
been shown not to carry clearly deleterious mutations
in BRCA1 (5 women in the sample carried missense
polymorphisms of unknown significance). No coding-
sequence alterations were detected in the nine exons of
MMAC1 in this sample set. In contrast, using the exact
same mutation-detection and analysis criteria on a sim-
ilarly ascertained set of non-Ashkenazi individuals with
breast cancer (without exclusion of BRCA1 carriers), we
would expect to detect seven deleterious mutations and
five missense polymorphisms of unknown significance in
BRCA1 (Shattuck-Eidens et al. 1997). Furthermore,
other than the four CS patients carrying germ-line mu-
tations in MMAC1 who have been described above, we
detected no sequence polymorphisms in the coding se-
quence of this gene in 1200 germ-line chromosomes,
and, in fact, we found only one sequence difference (si-
lent) between the human and chimpanzee sequences. If
the frequency of coding and proximal splice-junction
sequence variants in MMAC1 were 5% in the popula-
tion from which this sample was drawn, then we would
have had a 95% chance of detecting one or more such
variants.
Discussion
CS is distinct among autosomal dominant genetic syn-
dromes that predispose to the development of breast
cancer, since it has a unique cutaneous biomarker, the
trichilemmoma (Brownstein et al. 1977, 1978). Fur-
thermore, women with CS frequently give a history of
multiple breast biopsies for benign breast disease prior
to the development of breast cancer (Schrager et al., in
press). Most of these women did not have a family his-
tory of breast cancer. To date, the most well-described
association of CS with organ-specific cancer suscepti-
bility is that for the female breast (Brownstein et al.
1977; Schrager et al., in press). Other organs that appear
to develop cancer with increased frequency in CS include
the thyroid and the endometrium. In contrast to other
autosomal breast cancer–susceptibility syndromes, such
as the one associated with mutations in BRCA1 (Ford
et al. 1995), the development of ovarian cancer in this
syndrome is quite rare. However, CS shares with these
syndromes an earlier age at onset of breast cancer, as
well as an increased likelihood of bilateral breast cancer
(Schrager et al., in press).
Previous observations demonstrated linkage of CS to
chromosome 10q22-23 (Nelen et al. 1996). Further-
more, it is also now evident that mutations in a gene
(Liaw et al. 1997) known as “PTEN” (Li et al. 1997),
“MMAC1” (Steck et al. 1997), or “TEP1” (Li and Sun
1997), found in the CS critical interval on chromosome
10, are associated with CS individuals (Liaw et al. 1997).
In the observations reported here, we have identified
three new germ-line mutations in the coding sequence
of MMAC1 that are associated with CS, specifically in
individuals with CS and breast cancer. In two related
individuals with CS, we have described a frameshift mu-
tation in exon 7, resulting in a premature termination
codon, that is identical in an affected mother and her
affected daughter. ThisMMAC1mutation appears to be
associated with early-onset breast cancer, since one of
the two affected individuals developed breast cancer at
age 36 years. In a third affected individual, we identified
a 13-bp deletion in exon 8. Although this individual did
not develop breast cancer at an early age, she had a
history of bilateral breast cancer. Of interest is that she
also developed endometrial cancer while on tamoxifen.
Given that endometrial cancer has been associated with
CS (Starink et al. 1986) and with tamoxifen use (For-
nander et al. 1989), the contribution of both risk factors
to the development of disease in this one women is un-
known. However, this raises the possibility that the sub-
population of women who develop endometrial cancer
while on tamoxifen may have CS and/or mutations in
MMAC1. Finally, we identified a 3-bp insertion in exon
2 in another woman, who developed breast cancer at
age 33 years.
In the set of CS individuals that we have studied, we
have detected germ-line MMAC1 mutations in 4 indi-
viduals from 3 families but have not observed any cod-
ing-sequence alterations in the remaining 43 individuals
from 24 unrelated families. These data support our lim-
ited linkage information, suggesting that all CS families
may not show linkage to the locus identified on chro-
mosome 10. Although the experiments that we per-
formed do not rule out the possibility that either (a)
mutations in the 5′ regulatory regions or 3′ UTR of
MMAC1 or (b) other mechanisms (e.g., methylation si-
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lencing) that alter its expression level are associated with
CS, both the linkage data and the DNA-sequencing re-
sults support the idea that CS may be genetically het-
erogeneous. Tuberous sclerosis, another autosomal dom-
inant disorder associated with the formation of
hamartomas in the skin and other organs, has been
shown to be genetically heterogeneous, with distinct loci
located at chromosomes 9q34 (Haines et al. 1991) and
16p13.3 (Kandt et al. 1992). Our results suggest that
this may also be true for CS. Why this was not dem-
onstrated in the initial observations is not clear, but it
could be due to the ethnic backgrounds of the initial
families examined (Nelen et al. 1996; Liaw et al. 1997).
Moreover, certain of these individuals presented with CS
and LLD, which we have yet to identify in a CS proband
or in a CS family (Nelen et al. 1996; Liaw et al. 1997).
A strong case has been made for the existence of a
genetic mechanism regulating breast-tumor formation in
early-onset breast cancer (Claus et al. 1990). Indeed,
early-onset breast cancer has been associated with mu-
tations in BRCA1 (Miki et al. 1994) and BRCA2 (Woo-
ster et al. 1995). CS is associated with early-onset breast
cancer, and the cancer is usually ductal carcinoma
(Brownstein et al. 1977, 1978). Rachel Cowden, for
whom the syndrome is named, apparently died of breast
cancer at age 31 years (Lloyd and Dennis 1963; Brown-
stein et al. 1978). Herein we have identified MMAC1
mutations in two CS individuals with early-onset breast
cancer, as well as in one CS individual with bilateral
breast cancer. However, when we searched for germ-line
MMAC1 mutations in a subgroup of women with early-
onset breast cancer who lacked signs of CS and who
previously had been shown to have wild-type sequences
of BRCA1, we failed to detect any sequence variants.
These data suggest that germ-line mutations inMMAC1
occur infrequently, at least in this subpopulation of
early-onset breast cancer cases.
In summary, we have extended the observation that
MMAC1 mutations are associated with CS (Liaw et al.
1997), and we have demonstrated that MMAC1 mu-
tations appear to be associated with CS and breast can-
cer. However, we also have shown that certain families
and individuals with CS do not have mutations in the
coding sequence of MMAC1. Finally, we have failed to
detect MMAC1 mutations in a subpopulation of indi-
viduals with early-onset breast cancer, which suggests
that germ-line mutations in this gene do not appear to
be common, at least in a subpopulation of breast cancer
cases who also do not demonstrate mutations in
BRCA1.
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